Open Book Extracts will be leveraging Biopharmaceutical Research Company’s research platforms in order to develop research-backed formulations and products.
The new collaboration is aiming to build up the body of evidence surrounding the benefits of cannabinoids in order to support the cannabis industry.
Open Book Extracts and Biopharmaceutical Research Company will work closely together on preclinical and first-in-human (FIH) dosage forms, to optimisation of formulations for late-stage development and market following clinical evaluation.
Read more: Europe’s first cannabis tech accelerator to promote cannabis research
They will be developing the most appropriate formulation based on the physicochemical and biopharmaceutics properties of the cannabinoids of interest, the intended route of administration and the phase of development.
Open Book Extracts CEO, Dave Neundorfer, commented: “Current political and economic situations have created non-science-based products that are not serving today’s consumers, and are not designed to fill the research gaps we desperately need to fill to legitimise the emerging anecdotal evidence.
“Companies that base their brands on the research-backed formulations guided by science and develop corresponding products will rule global market share, and recreate how we choose to find therapeutic relief along with relaxation and stimulation.”
The partnership with BRC also supports the study of Delta-9 THC products and formulations, allowing OBX to identify the phase appropriate, optimal products for formulations including Delta-9 THC.
“We are excited to expand our research capabilities through our collaboration with BRC, in particular being able to add Delta-9 THC as a cannabinoid of interest for our formulation research,” said Neundorfer.
Open Book Extracts (OBX) has a 76,000 sqft research and production facility near Durham, North Carolina, and has developed proven methods to efficiently manufacture a broad range of cannabinoids from hemp and natural sources, including CBD, CBN, CBC, CBG, CBGa, CBT, CBDa, CBDv, and THCv.
Biopharmaceutical Research Company (BRC) CEO, George Hodgin, commented: “BRC is pleased to partner with OBX, joining forces to further build the body of evidence to support the cannabis industry.
“It is time we investigate the real science, and develop products for brands that take our culture to the next step. It will take a concerted effort. Developing appealing and effective cannabis-based products requires a multidisciplinary approach in food and pharma chemistry.
“BRC is a one-stop-shop for developing, modifying and improving these new products, and we’re excited to work with OBX to help bring novel, well-studied, effective products to consumers everywhere.”
[activecampaign form=31]
